We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HER2-positive breast cancer

News List

Seattle Genetics gets approval of TUKYSA in Switzerland for metastatic HER2-positive breast cancer pharmaceutical-business-review
May 15, 2020
Seattle Genetics announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA (tucatinib) tablets in combination with trastuzumab and capecitabine, for the treatment of patients with metastatic HER2-positive breast
FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer americanpharmaceuticalreview
March 05, 2020
The Food and Drug Administration (FDA) approved neratinib (NERLYNX, Puma Biotechnology) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer ...
Long-term data shows promise in breast cancer biosimilar pharmatimes
April 03, 2019
The a three-year follow-up study comparing biosimilar Ontruzant (trastuzumab) to a reference version - Herceptin - has found that the drug shows comparable overall survival and cardiac safety in early or locally advanced HER2-positive breast cancer.